Evogene Financial Results and Earnings Announcement Schedule for the Second Quarter of 2022
Evogene Ltd. (NASDAQ: EVGN) will release its financial results for Q2 2022 on August 31, 2022. A conference call will be held on the same day at 9:00 AM ET to discuss the results. The call can be accessed by dialing +1-888-281-1167 in the U.S. or +972-3-918-0609 internationally. Evogene, a computational biology company, utilizes advanced technologies to enhance life-science product development, focusing on microbes, small molecules, and genetic elements through its specialized engines: MicroBoost AI, ChemPass AI, and GeneRator AI.
- None.
- None.
REHOVOT, Israel, Aug. 2, 2022 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that it will release its financial results for the second quarter of 2022 on Wednesday, August 31, 2022.
On the day of the announcement, Company management will host a conference call to discuss the results at 9:00 AM Eastern time, 4:00 PM Israel time.
To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com.
A replay of the conference call will be available approximately two hours following the completion of the call. To access the replay, please dial +1-888-326-9310 toll free from the United States, or +972-3-925-5901 internationally. The replay will be accessible through September 2, 2022, and an archive of the webcast will be available on the webcast link for the following twelve months.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop novel products as follows: human microbiome-based therapeutics by Biomica Ltd., medical cannabis products by Canonic Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd.
For more information, please visit: www.evogene.com.
Investor Relations Contact:
Lital Mamon
Head of Marketing and PR
E: IR@evogene.com
T: +972-8-931-2097
Kenny Green
Investor Relations
E: IR@evogene.com
T: +1 212 378 8040
Logo - https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-financial-results-and-earnings-announcement-schedule-for-the-second-quarter-of-2022-301597792.html
SOURCE Evogene
FAQ
When will Evogene release its Q2 2022 financial results?
What time is the conference call for Evogene's Q2 2022 earnings?
How can I access the conference call for Evogene's financial results?
What technologies does Evogene use for product development?
